Login or Register
What's new
CANTOS One-Year Later
2018-09-17 by Prof Paul Ridker
The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) study continues to shed new light on the link between inflammation and atherosclerosis. Here, Trial Chairman Paul Ridker MD, talks to Cardio Debate about the latest results from the CANTOS …
Read more
CANTOS Update: IL-6 inhibition reduces atherothrombotic events
2018-09-12 by Sian Claire Owen, Dr Alberto Lorenzatti
New data from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) presented at the ESC 2018 provides ‘proof-of-concept evidence’ that modulating the interleukin-6 (IL-6) signalling pathway reduces rates of atherosclerotic events and mortality. [1] Catakinumab targets interleukin-1β, …
Read more
Aldosterone and abdominal obesity link can help improve treatment of heart failure
2018-09-09 by Sian Claire Owen, Prof Antoni Bayes-Genis, Dr Felipe Martinez
The link between aldosterone and obesity is well established, and this can help encourage the use of mineralocorticoid receptor antagonists in patients likely to respond to this treatment. Currently, only 10 to 25 percent of eligible …
Read more
2017-11-12 by Prof Angela Maas
Gender differences in cardiovascular disease are well established, especially as women reach the menopause. However, much needs to be done to educate the physicians to help them distinguish between stress-related hypertension and severe cases of …
Read more
2017-10-22
DOACs are a relatively new class of oral anticoagulants used to prevent blood clots. Warfarin is the traditional treatment, however its narrow therapeutic index and many contraindications with other drugs and foodstuffs means that it …
Read more
2017-10-15 by Prof Juan Tamargo
More must be done to address gender differences in cardiovascular drugs. Even in 2017, women are under-represented in randomised clinical trials. Professor Juan Tamargo, Professor of Pharmacology, Universidad Complutense, Madrid, Spain talks about the need to …
Read more
2015-06-23 by programme coordinator Dr Diego Kaski

This educational programme focuses on putative mechanistic links between epilepsy and cardiovascular disease, raises clinically relevant questions about anti-epileptic drug use in the context of cardiac disease, and addresses unresolved issues of practical importance in this area of “neuro-cardiology”.

Read more
2015-03-11 by programme coordinator Prof Juan Carlos Kaski

Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.

Read more
2012-07-05
Prof Ali Oto & Prof Antoni Martinez-Rubio talk to cadio-debate.com and discuss about novel anticoagulation agents. A Cardio Debate at the ISCP 17th International Congress.
Read more
2012-07-05
A round table discussion about the potential role of HDL-C in cardiovascular disease prevention: Prof JC Kaski, Prof Anthony S. Weirzbicki, Prof Lina Badimon and Prof Gillian W. Cockerill. Round table at 17th International Congress …
Read more
2012-07-05
Professor Albert Ferro, Kings College, London, UK, and Professor Peter Clemmensen, University of Copenhagen, Denmark discussed the role of antiplatelet agents in the management of acute coronary syndrome. Here, they are joined with Professor Juan …
Read more
Endothelial Dysfunction: Causes & Consequences, the Basis For Rational Management
Dr Luigi Gnudi, King's College of London, London, UK
Link between Endothelial Dysfunction and Systemic Hypertension
Prof Albert Ferro, Professor of Cardiovascular Clinical Pharmacology, Faculty of Life Sciences & Medicine (Cardiovascular Division), King's College London, UK
Endothelial dysfunction in coronary artery disease
Prof Julian Halcox, Professor of Cardiology at the Cardiff University, UK

Leave a Reply